Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty
Piper Sandler cut its price target for Amphastar Pharmaceuticals (NASDAQ: AMPH) from $25 to $21 while keeping a Neutral rating, TheFly reported May 11. The firm cited limited visibility on when pipeline programs will produce meaningful results. Amphastar’s May 7 Q1 ended March 31, 2026 net revenues were $171.2M; GAAP EPS $0.14 and adjusted EPS $0.42.
How this was made
The 30-second read
Why it matters
The immediate tradable signal is the reduced valuation anchor ($25→$21) tied to uncertainty over when pipeline programs will start contributing meaningfully.
Market read
For traders, this is a valuation/expectations reset rather than a fundamental operational shock: pipeline catalyst timing is the cited risk.
What to watch
Q1 profitability metrics (GAAP and adjusted) could support the stock if investors view near-term execution as stable while waiting for pipeline catalysts.
Background
The piece frames AMPH as undervalued and recent: Q1 FY2026 results were released May 7, followed by a May 11 analyst target reduction due to pipeline timing uncertainty.
Ticker impact
Piper Sandler cut its AMPH price target from $25 to $21 after AMPH’s quarterly results, citing limited visibility on pipeline catalyst timing.
Bias toward continued downside/underperformance vs. peers until clearer pipeline timing emerges.
The article’s actionable change is the downgrade in target (Neutral maintained), with the key driver explicitly being uncertainty on when pipeline programs will generate meaningful results.
Market effects
Reinforces that generic/proprietary pharma pipelines with complex products can trade on catalyst timing clarity, not just current-quarter earnings.
Primarily US small/mid-cap pharma sentiment; limited direct regional spillover implied.
Low—no global deal/regulatory catalyst mentioned beyond company-specific pipeline visibility.
Counterpoint
Despite the target cut, Piper Sandler kept a Neutral rating, implying the market may already be discounting pipeline uncertainty and downside may be limited.
Key entities
- companyAmphastar Pharmaceuticals, Inc.
US-listed biopharma focused on complex generics and proprietary injectables/inhalation/intranasal products.
- analyst_firmPiper Sandler
Cut AMPH price target from $25 to $21 while maintaining a Neutral stance.
